Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 2, 2014, Pages 211-222

  Leuci, Valeria ^a,b   Mesiano, Giulia ^a,b   Gammaitoni, Loretta ^b   Todorovic, Maja ^a,b   Giraudo, Lidia ^a,b   Carnevale Schianca, Fabrizio ^b   Aglietta, Massimo ^a,b   Sangiolo, Dario ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Adoptive immunotherapy; CIK; MHC unrestricted activity; NK; NKT

Indexed keywords

ANIMALS; ANTIGENS, NEOPLASM; CYTOKINE-INDUCED KILLER CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER T-CELLS; NEOPLASMS; PHENOTYPE;

EID: 84893483837     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113136660371     Document Type: Review

References (155)

1. June, C. H.; Blazar, B. R.; Riley, J. L. Engineering lymphocyte subsets: tools, trials and tribulations. Nat. Rev. Immunol., 2009, 9, 704-716.
2. Ramos, C. A.; Dotti, G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Exp. Opin. Biol. Ther., 2011, 11, 855-873.
3. Farag, S. S.; Caligiuri, M. A. Human natural killer cell development and biology. Blood Rev., 2006, 20, 123-137.
4. Galy, A.; Travis, M.; Cen, D.; Chen, B. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity, 1995, 3, 459-473.
5. Caligiuri, M. A. Human natural killer cells. Blood, 2008, 112, 461-469.
6. Lanier, L. L. NK cell recognition. Annu. Rev. Immunol., 2005, 23, 225-274.
7. Cooper, M. A.; Fehniger, T. A.; Caligiuri, M. A. The biology of human natural killer-cell subsets. Trends Immunol., 2001, 22, 633-640.
8. Moretta, L.; Moretta, A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J., 2004, 23, 255-259.
9. Lanier, L. L. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol., 2008, 9, 495-502.
10. Ruggeri, L.; Capanni, M.; Urbani, E.; Perruccio, K.; Shlomchik, W. D.; Tosti, A.; Posati, S.; Rogaia, D.; Frassoni, F.; Aversa, F.; Martelli, M. F.; Velardi, A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 2002, 295, 2097-2100.
11. Ruggeri, L.; Mancusi, A.; Capanni, M.; Martelli, M. F.; Velardi, A. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr. Opin. Immunol., 2005, 17, 211-217.
12. Pfeiffer, M.; Schumm, M.; Feuchtinger, T.; Dietz, K.; Handgretinger, R.; Lang, P. Intensity of HLA class I expression and KIR-mismatch determine NK-cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia. Br. J. Haematol., 2007, 138, 97-100.
13. Yu, J.; Heller, G.; Chewning, J.; Kim, S.; Yokoyama, W. M.; Hsu, K. C. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J. Immunol., 2007, 179, 5977-5989.
14. Geller, M. A.; Cooley, S.; Judson, P. L.; Ghebre, R.; Carson, L. F.; Argenta, P. A.; Jonson, A. L.; Panoskaltsis-Mortari, A.; Curtsinger, J.; McKenna, D.; Dusenbery, K.; Bliss, R.; Downs, L. S.; Miller, J. S. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy, 2011, 13, 98-107.
15. Geller, M. A.; Miller, J. S. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy, 2011, 3, 1445-1459.
16. Miller, J. S.; Soignier, Y.; Panoskaltsis-Mortari, A.; McNearney, S. A.; Yun, G. H.; Fautsch, S. K.; McKenna, D.; Le, C.; Defor, T. E.; Burns, L. J.; Orchard, P. J.; Blazar, B. R.; Wagner, J. E.; Slungaard, A.; Weisdorf, D. J.; Okazaki, I. J.; McGlave, P. B. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 2005, 105, 3051-3057.
17. Terunuma, H.; Deng, X.; Dewan, Z.; Fujimoto, S.; Yamamoto, N. Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int. Rev. Immunol., 2008, 27, 93-110.
18. Leibson, P. J. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity, 1997, 6, 655-661.
19. Musolino, A.; Naldi, N.; Bortesi, B.; Pezzuolo, D.; Capelletti, M.; Missale, G.; Laccabue, D.; Zerbini, A.; Camisa, R.; Bisagni, G.; Neri, T. M.; Ardizzoni, A. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol., 2008, 26, 1789-1796.
20. Bibeau, F.; Lopez-Crapez, E.; Di Fiore, F.; Thezenas, S.; Ychou, M.; Blanchard, F.; Lamy, A.; Penault-Llorca, F.; Frébourg, T.; Michel, P.; Sabourin, J. C.; Boissière-Michot, F. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol., 2009, 27, 1122-1129.
21. Roda, J. M.; Joshi, T.; Butchar, J. P.; McAlees, J. W.; Lehman, A.; Tridandapani, S.; Carson, W. E. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin. Cancer Res., 2007, 13, 6419-6428.
22. Rosenberg, S. A.; Lotze, M. T.; Muul, L. M.; Leitman, S.; Chang, A. E.; Ettinghausen, S. E.; Matory, Y. L.; Skibber, J. M.; Shiloni, E.; Vetto, J. T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med., 1985, 313, 1485-1492.
23. Rosenberg, S. A.; Lotze, M. T.; Muul, L. M.; Chang, A. E.; Avis, F. P.; Leitman, S.; Linehan, W. M.; Robertson, C. N.; Lee, R. E.; Rubin, J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med., 1987, 316, 889-897.
24. Rosenberg, S. A.; Lotze, M. T.; Yang, J. C.; Aebersold, P. M.; Linehan, W. M.; Seipp, C. A.; White, D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg., 1989, 210, 474-484.
25. Burns, L. J.; Weisdorf, D. J.; DeFor, T. E.; Vesole, D. H.; Repka, T. L.; Blazar, B. R.; Burger, S. R.; Panoskaltsis-Mortari, A.; Keever-Taylor, C. A.; Zhang, M. J.; Miller, J. S. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant., 2003, 32, 177-186.
26. Aversa, F.; Terenzi, A.; Tabilio, A.; Falzetti, F.; Carotti, A.; Ballanti, S.; Felicini, R.; Falcinelli, F.; Velardi, A.; Ruggeri, L.; Aloisi, T.; Saab, J. P.; Santucci, A.; Perruccio, K.; Martelli, M. P.; Mecucci, C.; Reisner, Y.; Martelli, M. F. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J. Clin. Oncol., 2005, 23, 3447-3454.
27. Ruggeri, L.; Capanni, M.; Mancusi, A.; Martelli, M. F.; Velardi, A: The impact of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation. Transpl. Immunol., 2005, 14, 203-206.
28. Cho, D.; Campana, D. Expansion and activation of natural killer cells for cancer immunotherapy. Korean J. Lab. Med., 2009, 29, 89-96.
29. Sutlu, T.; Alici, E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J. Intern. Med., 2009, 266, 154-181.
30. Smith, K. A. Interleukin-2. inception, impact, and implications. Science, 1988, 240, 1169-1176.
31. Fuchshuber, P. R.; Lotzová, E.; Pollock, R. E. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes. Lymphokine Cytokine Res., 1991, 10, 51-59.
32. Escudier, B.; Farace, F.; Angevin, E.; Charpentier, F.; Nitenberg, G.; Triebel, F.; Hercend, T. Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells. improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2. Eur. J. Cancer, 1994, 30A, 1078-1083.
33. Ishikawa, E.; Tsuboi, K.; Saijo, K.; Harada, H.; Takano, S.; Nose, T.; Ohno, T. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res., 2004, 24, 1861-1871.
34. Demagalhaes-Silverman, M.; Donnenberg, A.; Lembersky, B.; Elder, E.; Lister, J.; Rybka, W.; Whiteside, T.; Ball, E. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J. Immunother., 2000, 23, 154-160.
35. Lister, J.; Rybka, W. B.; Donnenberg, A. D.; DeMagalhaes-Silverman, M.; Pincus, SM.; Bloom, E. J.; Elder, E. M.; Ball, E. D.; Whiteside, T. L. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Clin. Cancer Res., 1995, 1, 607-614.
36. Alici, E.; Sutlu, T.; Björkstrand, B.; Gilljam, M.; Stellan, B.; Nahi, H.; Quezada, H. C.; Gahrton, G.; Ljunggren, H. G.; Dilber, M. S. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood, 2008, 111, 3155-3162.
37. Koehl, U.; Esser, R.; Zimmermann, S.; Tonn, T.; Kotchetkov, R.; Bartling, T.; Sörensen, J.; Grüttner, H. P.; Bader, P.; Seifried E.; Martin, H.; Lang, P.; Passweg, J. R.; Klingebiel, T.; Schwabe, D. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin. Padiatr., 2005, 217, 345-350.
38. Burns, L. J.; Weisdorf, D. J.; DeFor, T. E.; Repka, T. L.; Ogle, K. M.; Hummer, C.; Miller, J. S. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. Exp. Hematol., 2000, 28, 96-103.
39. Krause, S. W.; Gastpar, R.; Andreesen, R.; Gross, C.; Ullrich, H.; Thonigs, G.; Pfister, K.; Multhoff, G. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptideactivated.; autologous natural killer cells. A clinical phase I trial. Clin. Cancer Res., 2004, 10, 3699-3707.
40. Igarashi, T.; Wynberg, J.; Srinivasan, R.; Becknell, B.; McCoy, J. P.; Takahashi, Y.; Suffredini, D. A.; Linehan, W. M.; Caligiuri, M. A.; Childs, R. W. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood, 2004, 104, 170-177.
41. Dudley, M. E.; Wunderlich, J. R.; Robbins, P. F.; Yang, J. C.; Hwu, P.; Schwartzentruber, D. J.; Topalian, S. L.; Sherry, R.; Restifo, N. P.; Hubicki, A. M.; Robinson, M. R.; Raffeld, M.; Duray, P.; Seipp, C. A.; Rogers-Freezer, L.; Morton, K. E.; Mavroukakis, S. A.; White, D. E.; Rosenberg, S. A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 2002, 298, 850-854.
42. Dudley, M. E.; Wunderlich, J. R.; Yang, J. C.; Sherry, R. M.; Topalian, S. L.; Restifo, N. P.; Royal, R. E.; Kammula, U.; White, D. E.; Mavroukakis, S. A.; Rogers, L. J.; Gracia, G. J.; Jones, S. A.; Mangiameli, D. P.; Pelletier, M. M.; Gea-Banacloche, J.; Robinson, M. R.; Berman, D. M.; Filie, A. C.; Abati, A.; Rosenberg, S. A. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol., 2005, 23, 2346-2357.
43. Fehniger, T. A.; Caligiuri, M. A. Ontogeny and expansion of human natural killer cells. clinical implications. Int. Rev. Immunol., 2001, 20, 503-534.
44. Perez, S. A.; Sotiropoulou, P. A.; Gkika, D. G.; Mahaira, L. G.; Niarchos, D. K.; Gritzapis, A. D.; Kavalakis, Y. G.; Antsaklis, A. I.; Baxevanis, C. N.; Papamichail, M. A novel myeloid-like NK cell progenitor in human umbilical cord blood. Blood, 2003, 101, 3444-3450.
45. Perez, S. A.; Mahaira, L. G.; Demirtzoglou, F. J.; Sotiropoulou, P. A.; Ioannidis, P.; Iliopoulou, E. G.; Gritzapis, A. D.; Sotiriadou, N. N.; Baxevanis, C. N.; Papamichail, M. A potential role for hydrocortisone in the positive regulation of IL-15-activated NKcell proliferation and survival. Blood, 2005, 106, 158-166.
46. Ren, X. B.; Yu, J. P.; Cao, S.; Ren, B. Z.; Li, H.; Liu, H.; Min, W. P.; Hao, X. S. Antitumor effect of large doses IL-2-activated HLA haploidentical peripheral blood stem cells on refractory metastatic solid tumor treatment. Cancer Biother. Radiopharm., 2007, 22, 223-234.
47. Iliopoulou, E. G.; Kountourakis, P.; Karamouzis, M. V.; Doufexis, D.; Ardavanis, A.; Baxevanis, C. N.; Rigatos, G.; Papamichail, M.; Perez, S. A. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol. Immunother., 2010, 59, 1781-1789.
48. Brand, J. M.; Meller, B.; Von Hof, K.; Luhm, J.; Bähre, M.; Kirchner, H.; Frohn, C. Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma. Stem Cells Dev., 2004, 13, 307-314.
49. Berg, M.; Lundqvist, A.; McCoy, P.; Samsel, L.; Fan, Y.; Tawab, A.; Childs, R. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy, 2009, 11, 341-355.
50. Fujisaki, H.; Kakuda, H.; Shimasaki, N.; Imai, C.; Ma, J.; Lockey, T.; Eldridge, P.; Leung, W. H.; Campana, D. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res., 2009, 69, 4010-4017.
51. Seidel, M. G.; Freissmuth, M.; Pehamberger, H.; Micksche, M. Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro. synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2. Naunyn. Schmiedebergs Arch. Pharmacol., 1998, 358, 382-389.
52. Meazza, R.; Azzarone, B.; Orengo, A. M.; Ferrini, S. Role of common-gamma chain cytokines in NK cell development and function. perspectives for immunotherapy. J. Biomed. Biotechnol., 2011, 2011, 861920.
53. Imai, C.; Iwamoto, S.; Campana, D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood, 2005, 106, 376-383.
54. Cho, D.; Shook, D. R.; Shimasaki, N.; Chang, Y. H.; Fujisaki, H.; Campana, D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin. Cancer Res., 2010, 16, 3901-3909.
55. Berger, C.; Berger, M.; Hackman, R. C.; Gough, M.; Elliott, C.; Jensen, M. C.; Riddell, S. R. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood, 2009, 114, 2417-2426.
56. Waldmann, T. A.; Lugli, E.; Roederer, M.; Perera, L. P.; Smedley, J. V.; Macallister, R. P.; Goldman, C. K.; Bryant, B. R.; Decker, J. M.; Fleisher, T. A.; Lane, H. C.; Sneller, M. C.; Kurlander, R. J.; Kleiner, D. E.; Pletcher, J. M.; Figg, W. D.; Yovandich, J. L.; Creekmore, S. P. Safety (toxicity).; pharmacokinetics.; immunogenicity.; and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood, 2011, 117, 4787-4795.
57. Barao, I.; Hanash, A. M.; Hallett, W.; Welniak, L. A.; Sun, K.; Redelman, D.; Blazar, B. R.; Levy, R. B.; Murphy, W. J. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc. Natl. Acad. Sci. USA, 2006, 103, 5460-5465.
58. Bocian, K.; Borysowski, J.; Wierzbicki, P.; Wyzgal, J.; Klosowska, D.; Bialoszewska, A.; Paczek, L.; Górski, A.; Korczak-Kowalska, G. Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs. Nephrol. Dial. Transplant., 2010, 25, 710-717.
59. Hallett, W. H.; Ames, E.; Motarjemi, M.; Barao, I.; Shanker, A.; Tamang, D. L.; Sayers, T. J.; Hudig, D.; Murphy, W. J. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J. Immunol., 2008, 180, 163-170.
60. Lundqvist, A.; Yokoyama, H.; Smith, A.; Berg, M.; Childs, R. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood, 2009, 113, 6120-6127.
61. Romagné, F.; André, P.; Spee, P.; Zahn, S.; Anfossi, N.; Gauthier, L.; Capanni, M.; Ruggeri, L.; Benson, D. M.; Blaser, B. W.; Chiesa, M. D.; Moretta, A.; Vivier, E.; Caligiuri, M. A.; Velardi, A.; Wagtmann, N. Preclinical characterization of 1-7F9.; a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood, 2009, 114, 2667-2677.
62. Schmidt-Wolf, I. G.; Negrin, R. S.; Kiem, H. P.; Blume, K. G.; Weissman, I. L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med., 1991, 174, 139-149.
63. Lu, PH.; Negrin, R. S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol., 1994, 153, 1687-1696.
64. Schmidt-Wolf, I. G.; Lefterova, P.; Mehta, B. A.; Fernandez, L. P.; Huhn, D.; Blume, K. G.; Weissman, I. L.; Negrin, R. S. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp. Hematol., 1993, 21, 1673-1679.
65. Mesiano, G.; Todorovic, M.; Gammaitoni, L.; Leuci, V.; Giraudo Diego, L.; Carnevale-Schianca, F.; Fagioli, F.; Piacibello, W.; Aglietta, M.; Sangiolo, D. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Exp. Opin. Biol. Ther., 2012, 12, 673-684.
66. Hayes, M. P.; Wang, J.; Norcross, M. A. Regulation of interleukin-12 expression in human monocytes. Selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood, 1995, 86, 646-650.
67. Ma, X.; Chow, J. M.; Gri, G.; Carra, G.; Gerosa, F.; Wolf, S. F.; Dzialo, R.; Trinchieri G. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J. Exp. Med., 1996, 183, 147-157.
68. Lopez, R. D.; Waller, E. K.; Lu, P. H.; Negrin, R. S. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. Cancer Immunol. Immunother., 2001, 49, 629-640.
69. Ochoa, A. C.; Gromo, G.; Alter, B. J.; Sondel, P. M.; Bach, F. H. Long-term growth of lymphokine-activated killer (LAK) cells. role of anti-CD3, beta-IL 1, interferon-gamma and-beta. J. Immunol., 1987, 138, 2728-2733.
70. Anderson, P. M.; Bach, F. H.; Ochoa, A. C. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma. Cancer Immunol. Immunother., 1988, 27, 82-88.
71. Franceschetti, M.; Pievani, A.; Borleri, G.; Vago, L.; Fleischhauer, K.; Golay, J.; Introna, M. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp. Hematol., 2009, 37, 616-628 e612.
72. Sangiolo, D.; Martinuzzi, E.; Todorovic, M.; Vitaggio, K.; Vallario, A.; Jordaney, N.; Carnevale-Schianca, F.; Capaldi, A.; Geuna, M.; Casorzo, L.; Nash, R. A.; Aglietta, M.; Cignetti, A. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells. implications for their infusion across major HLA barriers. Int. Immunol., 2008, 20, 841-848.
73. Leemhuis, T.; Wells, S.; Scheffold, C.; Edinger, M.; Negrin, R. S. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol. Blood Marrow Transplant., 2005, 11, 181-187.
74. Baker, J.; Verneris, M. R.; Ito, M.; Shizuru, J. A.; Negrin, R. S. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood, 2001, 97, 2923-2931.
75. Zoll, B.; Lefterova, P.; Csipai, M.; Finke, S.; Trojaneck, B.; Ebert, O.; Micka, B.; Roigk, K.; Fehlinger, M.; Schmidt-Wolf, G. D.; Huhn, D.; Schmidt-Wolf, I. G. Generation of cytokine-induced killer cells using exogenous interleukin-2,-7 or-12. Cancer Immunol. Immunother., 1998, 47, 221-226.
76. Bonanno, G.; Iudicone, P.; Mariotti, A.; Procoli, A.; Pandolfi, A.; Fioravanti, D.; Corallo, M.; Perillo, A.; Scambia, G.; Pierelli, L.; Rutella, S. Thymoglobulin, interferon-gamma and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinicalgrade cultures. J. Transl. Med., 2010, 8, 129.
77. Rettinger, E.; Kuçi, S.; Naumann, I.; Becker, P.; Kreyenberg, H.; Anzaghe, M.; Willasch, A.; Koehl, U.; Bug, G.; Ruthardt, M.; Klingebiel, T.; Fulda, S.; Bader, P. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy, 2012, 14(1), 91-103.
78. Todorovic, M.; Gammaitoni, L.; Leuci, V.; Giraudo Diego, L.; Carnevale-Schianca, F.; Gallo, S.; Fagioli, F.; Cignetti, A.; Aglietta, M.; Sangiolo, D. Ex-vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across MHC-barriers. In EHA, 2011 [E-Pub Ahead of Scheduale].
79. Introna, M.; Franceschetti, M.; Ciocca, A.; Borleri, G.; Conti, E.; Golay, J.; Rambaldi, A. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant., 2006, 38, 621-627.
80. Introna, M.; Borleri, G.; Conti, E.; Franceschetti, M.; Barbui, A. M.; Broady, R.; Dander, E.; Gaipa, G.; D'Amico, G.; Biagi, E.; Parma, M.; Pogliani, E. M.; Spinelli, O.; Baronciani, D.; Grassi, A.; Golay, J.; Barbui, T.; Biondi, A.; Rambaldi, A. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation. a phase I study. Haematologica, 2007, 92, 952-959.
81. Schmidt-Wolf, I. G.; Lefterova, P.; Johnston, V.; Huhn, D.; Blume, K. G.; Negrin, R. S. Propagation of large numbers of T cells with natural killer cell markers. Br. J. Haematol., 1994, 87, 453-458.
82. Karimi, M.; Cao, T. M.; Baker, J. A.; Verneris, M. R.; Soares, L.; Negrin, RS. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J. Immunol., 2005, 175, 7819-7828.
83. Verneris, M. R.; Karami, M.; Baker, J.; Jayaswal, A.; Negrin, R. S. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood, 2004, 103, 3065-3072.
84. Jamieson, A. M.; Diefenbach, A.; McMahon, C. W.; Xiong, N.; Carlyle, J. R.; Raulet, D. H. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity, 2002, 17, 19-29.
85. Diefenbach, A.; Jamieson, A. M.; Liu, S. D.; Shastri, N.; Raulet, D. H. Ligands for the murine NKG2D receptor. expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol., 2000, 1, 119-126.
86. Cosman, D.; Mullberg, J.; Sutherland, C. L.; Chin, W.; Armitage, R.; Fanslow, W.; Kubin, M.; Chalupny, N. J. ULBPs.; novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity, 2001, 14, 123-133.
87. Groh, V.; Rhinehart, R.; Secrist, H.; Bauer, S.; Grabstein, K. H.; Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA., 1999, 96, 6879-6884.
88. Pievani, A.; Borleri, G.; Pende, D.; Moretta, L.; Rambaldi, A.; Golay, J.; Introna, M. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood, 2011, 118, 3301-3310.
89. Schmidt-Wolf, I. G.; Lefterova, P.; Johnston, V.; Scheffold, C.; Csipai, M.; Mehta, BA.; Tsuruo, T.; Huhn, D.; Negrin, R. S. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol., 1996, 169, 85-90.
90. Margolin, K, A.; Negrin, R. S.; Wong, K. K.; Chatterjee, S.; Wright C.; Forman S. J. Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol. Rev., 1997, 157, 231-240.
91. Schmidt-Wolf, I. G.; Finke, S.; Trojaneck, B.; Denkena, A.; Lefterova, P.; Schwella, N.; Heuft, H. G.; Prange, G.; Korte, M.; Takeya, M.; Dorbic, T.; Neubauerm A.; Wittig, B.; Huhn, D. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer.; colorectal cancer and lymphoma. Br. J. Cancer, 1999, 81, 1009-1016.
92. Olioso, P.; Giancola, R.; Di Riti, M.; Contento, A.; Accorsi, P.; Iacone, A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol. Oncol., 2009, 27(3), 130-139.
93. Wu, C.; Jiang, J.; Shi, L.; Xu, N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res., 2008, 28, 3997-4002.
94. Hui, D.; Qiang, L.; Jian, W.; Ti, Z.; Da-Lu, K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig. Liver Dis., 2009, 41, 36-41.
95. Weng, D. S.; Zhou, J.; Zhou Q. M.; Zhao, M.; Wang Q. J.; Huang, L. X.; Li, Y. Q.; Chen, S. P.; Wu, P. H.; Xia, J. C. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J. Immunother., 2008, 31, 63-71.
96. Shi, M.; Zhang, B.; Tang, Z. R.; Lei, Z. Y.; Wang, H. F.; Feng, Y. Y.; Fan, Z. P.; Xu, D. P.; Wang, F. S. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J. Gastroenterol., 2004, 10, 1146-1151.
97. Liu, L.; Zhang, W.; Qi, X.; Li, H.; Yu, J.; Wei, S.; Hao, X.; Ren, X. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin. Cancer Res., 2012.
98. Hontscha, C.; Borck, Y.; Zhou, H.; Messmer, D.; Schmidt-Wolf, I. G. Clinical trials on CIK cells. first report of the international registry on CIK cells (IRCC). J. Cancer Res. Clin. Oncol., 2011, 137, 305-310.
99. Chan, J. K.; Hamilton, C. A.; Cheung, M. K.; Karimi, M.; Baker, J.; Gall, J. M.; Schulz, S.; Thorne, S. H.; Teng, N. N.; Contag, C. H.; Lum, L. G.; Negrin, R. S. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin. Cancer Res., 2006, 12, 1859-1867.
100. Verneris, M. R.; Arshi, A.; Edinger, M.; Kornacker, M.; Natkunam, Y.; Karami, M.; Cao, Y. A.; Marina, N.; Contag, C. H.; Negrin, R. S. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin. Cancer Res., 2005, 11, 4561-4570.
101. Kornacker, M.; Verneris, M.; Kornacker, B.; Ganten, T.; Scheffold, C.; Negrin, R. The apoptotic and proliferative fate of cytokineinduced killer cells after redirection to tumor cells with bispecific Ab. Cytotherapy, 2006, 8, 13-23.
102. Marin, V.; Kakuda, H.; Dander, E.; Imai, C.; Campana, D.; Biondi, A.; D'Amico, G. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. Exp. Hematol., 2007, 35, 1388-1397.
103. Elia, A.; Inghirami, G.; Circosta.; P. C.; P. S.; D. S.; C. T.; A. C. Retargeting of citokine-induced killer (cik) cells with molecularly engrafted t-cell receptors (TCR). A Preclinical in Vitro and In Vivo Study. In American Society of Hematology, San Diego, CA, USA. Blood. 2011.
104. Verneris, M. R.; Ito, M.; Baker, J.; Arshi, A.; Negrin, R. S.; Shizuru, J. A. Engineering hematopoietic grafts. purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol. Blood Marrow Transplant., 2001, 7, 532-542.
105. Laport, G. G.; Sheehan, K.; Baker, J.; Armstrong, R.; Wong, R. M.; Lowsky, R.; Johnston, L. J.; Shizuru, J. A.; Miklos, D.; Arai, S.; Benjamin, J. E.; Weng, W. K.; Negrin, R. S. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant., 2011, 17(11), 1679-1687.
106. Porcelli, S.; Yockey, C. E.; Brenner, M. B.; Balk, S. P. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8-alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J. Exp. Med., 1993, 178, 1-16.
107. Lantz, O.; Bendelac, A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8-T cells in mice and humans. J. Exp. Med., 1994, 180, 1097-1106.
108. Bendelac, A.; Killeen, N.; Littman, D. R.; Schwartz, R. H. A subset of CD4+ thymocytes selected by MHC class I molecules. Science, 1994, 263, 1774-1778.
109. Bendelac, A. CD1: presenting unusual antigens to unusual T lymphocytes. Science, 1995, 269, 185-186.
110. Roark, J. H.; Park, S. H.; Jayawardena, J.; Kavita, U.; Shannon, M.; Bendelac, A. CD1. 1 expression by mouse antigen-presenting cells and marginal zone B cells. J. Immunol., 1998, 160, 3121-3127.
111. Bendelac, A. Positive selection of mouse NK1+ T cells by CD1-expressing cortical thymocytes. J. Exp. Med., 1995, 182, 2091-2096.
112. Kawano, T.; Nakayama, T.; Kamada, N.; Kaneko, Y.; Harada, M.; Ogura, N.; Akutsu, Y.; Motohashi, S.; Iizasa, T.; Endo, H.; Fujisawa, T.; Shinkai, H.; Taniguchi, M. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res., 1999, 59, 5102-5105.
113. Metelitsa, L. S.; Naidenko, O. V.; Kant, A.; Wu, H. W.; Loza, M. J.; Perussia, B.; Kronenberg, M.; Seeger, R. C. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol., 2001, 167, 3114-3122.
114. Nieda, M.; Nicol, A.; Koezuka, Y.; Kikuchi, A.; Lapteva, N.; Tanaka, Y.; Tokunaga, K.; Suzuki, K.; Kayagaki, N.; Yagita, H.; Hirai, H.; Juji, T. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood, 2001, 97, 2067-2074.
115. Gumperz, J. E.; Miyake, S.; Yamamura, T.; Brenner, M. B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med., 2002, 195, 625-636.
116. Wilson, S. B.; Delovitch, T. L. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol., 2003, 3, 211-222.
117. Van der Vliet, H. J.; Molling, J. W.; von Blomberg, B. M.; Nishi, N.; Kölgen, W.; Van den Eertwegh, A. J.; Pinedo, H. M.; Giaccone, G.; Scheper, R. J. The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin. Immunol., 2004, 112, 8-23.
118. Carnaud, C.; Lee, D.; Donnars, O.; Park, S. H.; Beavis, A.; Koezuka, Y.; Bendelac, A. Cutting edge. Cross-talk between cells of the innate immune system. NKT cells rapidly activate NK cells. J. Immunol., 1999, 163, 4647-4650.
119. Taniguchi, M.; Seino, K.; Nakayama, T. The NKT cell system. bridging innate and acquired immunity. Nat. Immunol., 2003, 4, 1164-1165.
120. Yoshimoto, T.; Bendelac, A.; Watson, C.; Hu-Li, J.; Paul, W. E. Role of NK1. 1+ T cells in a TH2 response and in immunoglobulin E production. Science, 1995, 270, 1845-1847.
121. Hammond, K. J.; Pelikan, S. B.; Crowe, N. Y.; Randle-Barrett, E.; Nakayama, T.; Taniguchi, M.; Smyth, M. J.; van Driel, I. R.; Scollay, R.; Baxter, A. G.; Godfrey, D. I. NKT cells are phenotypically and functionally diverse. Eur. J. Immunol., 1999, 29, 3768-3781.
122. Lee, P. T.; Benlagha, K.; Teyton, L.; Bendelac, A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J. Exp. Med., 2002, 195, 637-641.
123. Crowe, N. Y.; Uldrich, A. P.; Kyparissoudis, K.; Hammond, K. J.; Hayakawa, Y.; Sidobre, S.; Keating, R.; Kronenberg, M.; Smyth, M. J.; Godfrey, D. I. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J. Immunol., 2003, 171, 4020-4027.
124. Toura, I.; Kawano, T.; Akutsu, Y.; Nakayama, T.; Ochiai, T.; Taniguchi, M. Cutting edge. inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J. Immunol., 1999, 163, 2387-2391.
125. Akutsu, Y.; Nakayama, T.; Harada, M.; Kawano, T.; Motohashi, S.; Shimizu, E.; Ito, T.; Kamada, N.; Saito, T.; Matsubara, H.; Miyazawa, Y.; Ochiai, T.; Taniguchi, M. Expansion of lung V alpha 14 NKT cells by administration of alpha-galactosylceramidepulsed dendritic cells. Jpn. J. Cancer Res., 2002, 93, 397-403.
126. Motohashi, S.; Kobayashi, S.; Ito, T.; Magara, K. K.; Mikuni, O.; Kamada, N.; Iizasa, T.; Nakayama, T.; Fujisawa, T.; Taniguchi, M. Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients. Int. J. Cancer, 2002, 102, 159-165.
127. Giaccone, G.; Punt, C. J.; Ando, Y.; Ruijter, R.; Nishi, N.; Peters, M.; von Blomberg, B. M.; Scheper, R. J.; Van der Vliet, H. J.; Van den Eertwegh, A. J.; Roelvink, M.; Beijnen, J.; Zwierzina, H.; Pinedo, H. M. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res., 2002, 8, 3702-3709.
128. Nakagawa, R.; Motoki, K.; Nakamura, H.; Ueno, H.; Iijima, R.; Yamauchi, A.; Tsuyuki, S.; Inamoto, T.; Koezuka, Y. Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production. Oncol. Res., 1998, 10, 561-568.
129. Nakagawa, R.; Motoki, K.; Ueno, H.; Iijima, R.; Nakamura, H.; Kobayashi, E.; Shimosaka, A.; Koezuka, Y. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alphagalactosylceramide.; KRN7000. Cancer Res., 1998, 58, 1202-1207.
130. Ishikawa, A.; Motohashi, S.; Ishikawa, E.; Fuchida, H.; Higashino, K.; Otsuji, M.; Iizasa, T.; Nakayama, T.; Taniguchi, M.; Fujisawa, T. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res., 2005, 11, 1910-1917.
131. Motohashi, S.; Ishikawa, A.; Ishikawa, E.; Otsuji, M.; Iizasa, T.; Hanaoka, H.; Shimizu, N.; Horiguchi, S.; Okamoto, Y.; Fujii, S.; Taniguchi, M.; Fujisawa, T.; Nakayama, T. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res., 2006, 12, 6079-6086.
132. Motohashi, S.; Nagato, K.; Kunii, N.; Yamamoto, H.; Yamasaki, K.; Okita, K.; Hanaoka, H.; Shimizu, N.; Suzuki, M.; Yoshino, I.; Taniguchi, M.; Fujisawa, T.; Nakayama, T. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J. Immunol., 2009, 182, 2492-2501.
133. Nagato, K.; Motohashi, S.; Ishibashi, F.; Okita, K.; Yamasaki, K.; Moriya, Y.; Hoshino, H.; Yoshida, S.; Hanaoka, H.; Fujii, S.; Taniguchi, M.; Yoshino, I.; Nakayama, T. Accumulation of activated invariant natural killer T cells in the tumor microenvironment after alpha-galactosylceramide-pulsed antigen presenting cells. J. Clin. Immunol., 2012, 32, 1071-1081.
134. Chang, D. H.; Osman, K.; Connolly, J.; Kukreja, A.; Krasovsky, J.; Pack, M.; Hutchinson, A.; Geller, M.; Liu, N.; Annable, R.; Shay, J.; Kirchhoff, K.; Nishi, N.; Ando, Y.; Hayashi, K. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med., 2005, 201, 1503-1517.
135. Uchida, T.; Horiguchi, S.; Tanaka, Y.; Yamamoto, H.; Kunii, N.; Motohashi, S.; Taniguchi, M.; Nakayama, T.; Okamoto, Y. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol. Immunother., 2008, 57, 337-345.
136. Rogers, P. R.; Matsumoto, A.; Naidenko, O.; Kronenberg, M.; Mikayama, T.; Kato, S. Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000. J. Immunol. Methods, 2004, 285, 197-214.
137. Takahashi, T.; Chiba, S.; Nieda, M.; Azuma, T.; Ishihara, S.; Shibata, Y.; Juji, T.; Hirai, H. Cutting edge: Analysis of human V alpha 24+CD8+ NK T cells activated by alpha-galactosylceramidepulsed monocyte-derived dendritic cells. J. Immunol., 2002, 168, 3140-3144.
138. Kunii, N.; Horiguchi, S.; Motohashi, S.; Yamamoto, H.; Ueno, N.; Yamamoto, S.; Sakurai, D.; Taniguchi, M.; Nakayamam T.; Okamoto, Y. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci., 2009, 100, 1092-1098.
139. Willemsen, R. A.; Debets, R.; Chames, P.; Bolhuis, R. L. Genetic engineering of T cell specificity for immunotherapy of cancer. Hum. Immunol., 2003, 64, 56-68.
140. Jena, B.; Dotti, G.; Cooper, L. J. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood, 2010, 116, 1035-1044.
141. Casucci, M.; Bondanza, A. Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes. J. Cancer, 2011, 2, 378-382.
142. Kohn, D. B.; Dotti, G.; Brentjens, R.; Savoldo, B.; Jensen, M.; Cooper, L. J. N.; June, C. H.; Rosenberg, S.; Sadelain, M.; Heslop, H. E. CARs on track in the clinic. Am. Soc. Gene Cell Therapy, 2011, 19, 432-438.
143. Brentjens, R. J.; Curran, K. J. Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematology Am. Soc. Hematol. Educ. Prog., 2012, 2012, 143-151.
144. Tassev, D. V.; Cheng, M.; Cheung, N. K. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther., 2012, 19, 84-100.
145. Torikai, H.; Reik, A.; Liu, P. Q.; Zhou, Y.; Zhang, L.; Maiti, S.; Huls, H.; Miller, J. C.; Kebriaei, P.; Rabinovitch, B.; Lee, D. A.; Champlin, R. E.; Bonini, C.; Naldini, L.; Rebar, E. J.; Gregory, P. D.; Michael, C. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimericantigen-receptor and eliminate expression of endogenous TCR. Blood, 2012, 119, 5697-5705.
146. Yoon, S. H.; Lee, J. M.; Woo, S. J.; Park, M. J.; Park, J. S.; Kim, H. S.; Park, M. Y.; Sohn, H. J.; Kim, T. G. Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR). J. Clin. Immunol., 2009, 29, 806-814.
147. Barkholt, L.; Alici, E.; Conrad, R.; Sutlu, T.; Gilljam, M.; Stellan, B.; Christensson, B.; Guven, H.; Björkström, N. K.; Söderdahl, G.; Cederlund, K.; Kimby, E.; Aschan, J.; Ringdén, O.; Ljunggren, H. G.; Dilber, M. S. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy, 2009, 1, 753-764.
148. Parkhurst, M. R.; Riley, J. P.; Igarashi, T.; Li, Y.; Robbins, P. F.; Rosenberg, S. A. Immunization of patients with the hTERT: 540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin. Cancer Res., 2004, 10, 4688-4698.
149. Curti, A.; Ruggeri, L.; D'Addio, A.; Bontadini, A.; Dan, E.; Motta, M. R.; Trabanelli, S.; Giudice, V.; Urbani, E.; Martinelli, G.; Paolini, S.; Fruet, F.; Isidori, A.; Parisi, S.; Bandini, G.; Baccarani, M.; Velardi, A.; Lemoli, R. M. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood, 2011, 118, 3273-3279.
150. Arai, S.; Klingemann, H. G. Role of immunotherapy in stem cell transplantation. Int. J. Hematol., 2003, 77, 22-28.
151. Rubnitz, J. E.; Inaba, H.; Ribeiro, R. C.; Pounds, S.; Rooney, B.; Bell, T.; Pui, C. H.; Leung, W. NKAML: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol., 2010, 28, 955-959.
152. Brehm, C.; Huenecke, S.; Quaiser, A.; Esser, R.; Bremm, M.; Kloess, S.; Soerensen, J.; Kreyenberg, H.; Seidl, C.; Becker, P. S.; Mühl, H.; Klingebiel, T.; Bader, P.; Passweg, J. R.; Schwabe, D.; Koehl, U. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. PLoS One, 2011, 6, e27351.
153. Jiang, J.; Xu, N.; Wu, C.; Deng, H.; Lu, M.; Li, M.; Xu, B.; Wu, J.; Wang, R.; Xu, J.; Nilsson-Ehle, P. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokineinduced killer cells. Anticancer Res., 2006, 26, 2237-2242.
154. Niu, Q.; Wang, W.; Li, Y.; Qin, S.; Wang, Y.; Wan, G.; Guan, J.; Zhu, W. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int. Immunopharmacol., 2011, 11, 449-456.
155. Jiang, J. T.; Shen, Y. P.; Wu, C. P.; Zhu, Y. B.; Wei, W. X.; Chen, L. J.; Zheng, X.; Sun, J.; Lu, B. F.; Zhang, X. G. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J. Gastroenterol., 2010, 16, 6155-6162.